Successful Treatment of Lichen Amyloidosis Using a Fixed Combination of Halobetasol-Propionate and Tazarotene Lotion

被引：0
|
作者：
Shoen, Ezra [1 ]
Hou, Angela [1 ]
Zahn, Joseph [1 ]
Friedman, Adam [1 ]
机构：
[1] George Washington Univ, Sch Med & Hlth Sci, Washington, DC 20052 USA
来源：
JOURNAL OF DRUGS IN DERMATOLOGY | 2021年 / 20卷 / 03期
关键词：
D O I：
10.36849/IDD.2021.5794
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：336 / 337
页数：2
相关论文
共 50 条
  • [21] Halobetasol and Tazarotene: Further Defining the Role of a Unique Fixed Combination Topical Lotion in Moderate-to-Severe Plaque Psoriasis
    Gold, Linda Stein
    Bagel, Jerry
    Lebwohl, Mark G.
    Lin, Tina
    Martin, Gina
    Pillai, Radhakrishnan
    JOURNAL OF DRUGS IN DERMATOLOGY, 2018, 17 (12) : 1290 - 1296
  • [22] Efficacy of a Once-Daily Fixed Combination Halobetasol (0.01%) and Tazarotene (0.045%) Lotion in the Treatment of Localized Moderate-to-Severe Plaque Psoriasis
    Blauvelt, Andrew
    Green, Lawrence J.
    Lebwohl, Mark G.
    Yamauchi, Paul S.
    Lin, Tina
    Martin, Gina
    Pillai, Radhakrishnan
    JOURNAL OF DRUGS IN DERMATOLOGY, 2019, 18 (03) : 297 - 299
  • [23] Safety and Efficacy of a Fixed Combination Halobetasol and Tazarotene Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Pooled Analysis of Two Phase 3 Studies
    Sugarman, Jeffrey L.
    Weiss, Jonathan
    Tanghetti, Emil A.
    Bagel, Jerry
    Yamauchi, Paul S.
    Gold, Linda Stein
    Lin, Tina
    Martin, Gina
    Pillai, Radhakrishnan
    Israel, Robert
    JOURNAL OF DRUGS IN DERMATOLOGY, 2018, 17 (08) : 855 - 861
  • [24] Halobetasol and tazarotene: Further defining the role of a unique fixed combination topical lotion in moderate-to-severe plaque psoriasis in a Hispanic population
    Yamauchi, Paul S.
    Bhatia, Neal D.
    Green, Lawrence J.
    Lin, Tina
    Martin, Gina
    Harris, Susan
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB218 - AB218
  • [25] Maintenance of skin clearance in a long-term open-label study of fixed-combination halobetasol propionate and tazarotene lotion for psoriasis in participants with prior use of topical treatments
    Gold, Linda Stein
    Alonso-Llamazares, Javier
    Zeichner, Joshua
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB79 - AB79
  • [26] Fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% (HP/TAZ) lotion for the treatment of plaque psoriasis in patients with 3-5% body surface area (BSA) and poor quality of life (QoL)
    Gold, Linda Stein
    Lain, Edward
    Bagel, Jerry
    Jacobson, Abby
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB156 - AB156
  • [27] Long-Term Multiple Center Experience in Treating Plaque Psoriasis With Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion
    Abduelmula, Abrahim
    Gooderham, Melinda J.
    JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2023, 27 (03) : 293 - 294
  • [28] Breaking the Frustrating Cycle of Topical Steroids in Psoriasis: A Review of a Novel Vehicle for Fixed-Dose Combination Halobetasol Propionate/Tazarotene
    Kircik, Leon
    Bhatia, Neal
    Lain, Edward
    Jacobson, Abby
    JOURNAL OF DRUGS IN DERMATOLOGY, 2023, 22 (03) : 247 - 251
  • [29] Treating Psoriasis With Halobetasol Propionate and Tazarotene Combination: A Review of Phase II and III Clinical Trials
    Ramachandran, Vignesh
    Bertus, Brooke
    Bashyam, Arjun M.
    Feldman, Steven R.
    ANNALS OF PHARMACOTHERAPY, 2020, 54 (09) : 872 - 878
  • [30] Long-term management of moderate to severe plaque psoriasis: Maintenance of treatment success following cessation of fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in patients with baseline body surface area of 6%-12%
    Gold, Linda Stein
    Weiss, Jonathan S.
    Green, Lawrence J.
    Kircik, Leon
    Lin, Tina
    Harris, Susan
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB36 - AB36
12345